Synergistic antipruritic effects of gamma aminobutyric acid A and B agonists in a mouse model of atopic dermatitis.
Synergistic antipruritic effects of gamma aminobutyric acid A and B agonists in a mouse model of atopic dermatitis.
复制标题
DOI:
10.1016/j.jaci.2017.02.001
复制
发表时间:
2017-08
期刊:
影响因子:
--
通讯作者:
Basbaum AI
中科院分区:
文献类型:
--
作者:
Cevikbas F;Braz JM;Wang X;Solorzano C;Sulk M;Buhl T;Steinhoff M;Basbaum AI
Despite recent insights into the pathophysiology of acute and chronic itch, chronic itch remains an often intractable condition. Among major contributors to chronic itch is dysfunction of spinal cord GABAergic inhibitory controls. To test the hypothesis that selective GABA agonists as well as cell transplant-derived GABA are antipruritic against acute itch and in a transgenic mouse model of atopic dermatitis produced by overexpression of the TH2 cell-associated cytokine, IL-31 (IL-31Tg mice). We injected wild-type and IL-31Tg mice with combinations of GABA-A (muscimol) or GABA-B (baclofen) receptor agonists 15–20 min prior to injection of various pruritogens (histamine, chloroquine or endothelin-1) and recorded spontaneous scratching before and after drug administration. We also tested the antipruritic properties of intraspinal transplantation of precursors of GABAergic interneurons in the IL-31Tg mice. Systemic muscimol or baclofen are antipruritic against both histamine-dependent and independent pruritogens, but the therapeutic window using either ligand alone was very small. In contrast, combined subthreshold doses of baclofen and muscimol produced a significant synergistic antipruritic effect, with no sedation. Finally, transplant-mediated long term enhancement of GABAergic signaling not only reduced spontaneous scratching in the IL-31Tg mice but also dramatically resolved the associated skin lesions. Although additional research is clearly needed, existing approved GABA agonists should be considered in the management of chronic itch, notably atopic dermatitis.
登录
查看更多内容
DOI:
10.1007/978-3-662-44605-8_18
发表时间:
2015-01-01
期刊:
PHARMACOLOGY OF ITCH
影响因子:
--
作者:
Leslie, Tabi Anika;Greaves, Malcolm W.;Yosipovitch, Gil
通讯作者:
Yosipovitch, Gil
影响因子:
3.3
作者:
Akiyama T;Carstens E
通讯作者:
Carstens E
影响因子:
16.2
作者:
Kardon AP;Polgár E;Hachisuka J;Snyder LM;Cameron D;Savage S;Cai X;Karnup S;Fan CR;Hemenway GM;Bernard CS;Schwartz ES;Nagase H;Schwarzer C;Watanabe M;Furuta T;Kaneko T;Koerber HR;Todd AJ;Ross SE
通讯作者:
Ross SE
影响因子:
25
作者:
Han, Liang;Ma, Chao;Liu, Qin;Weng, Hao-Jui;Cui, Yiyuan;Tang, Zongxiang;Kim, Yushin;Nie, Hong;Qu, Lintao;Patel, Kush N.;Li, Zhe;McNeil, Benjamin;He, Shaoqiu;Guan, Yun;Xiao, Bo;LaMotte, Robert H.;Dong, Xinzhong
通讯作者:
Dong, Xinzhong
影响因子:
15.9
作者:
Braz, Joao M.;Juarez-Salinas, Dina;Basbaum, Allan I.
通讯作者:
Basbaum, Allan I.